Your browser doesn't support javascript.
loading
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.
Jering, Karola S; Claggett, Brian; Pfeffer, Marc A; Granger, Christopher; Køber, Lars; Lewis, Eldrin F; Maggioni, Aldo P; Mann, Douglas; McMurray, John J V; Rouleau, Jean-Lucien; Solomon, Scott D; Steg, Philippe G; van der Meer, Peter; Wernsing, Margaret; Carter, Katherine; Guo, Weinong; Zhou, Yinong; Lefkowitz, Martin; Gong, Jianjian; Wang, Yi; Merkely, Bela; Macin, Stella M; Shah, Urmil; Nicolau, Jose C; Braunwald, Eugene.
Afiliación
  • Jering KS; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Claggett B; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Pfeffer MA; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Granger C; Duke University Medical Center, Durham, NC, USA.
  • Køber L; Rigshospitalet, Copenhagen, Denmark.
  • Lewis EF; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA.
  • Maggioni AP; ANMCO Research Center, Florence, Italy.
  • Mann D; Washington University Medical Center, St Louis, MO, USA.
  • McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Rouleau JL; Montreal Heart Institute, University of Montreal, Montreal, Canada.
  • Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Steg PG; Université de Paris, AP-HP (Assistance Publique-Hôpitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148, Paris, France.
  • van der Meer P; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Wernsing M; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Carter K; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Guo W; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Zhou Y; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Lefkowitz M; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Gong J; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Wang Y; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
  • Merkely B; Semmelweis University, Heart and Vascular Center, Budapest, Hungary.
  • Macin SM; Instituto de Cardiología JF Cabral Corrientes, Corrientes, Argentina.
  • Shah U; Care Institute of Medical Sciences, Ahmedabad, India.
  • Nicolau JC; Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Braunwald E; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Eur J Heart Fail ; 23(6): 1040-1048, 2021 06.
Article en En | MEDLINE | ID: mdl-33847047
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Insuficiencia Cardíaca / Infarto del Miocardio Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Insuficiencia Cardíaca / Infarto del Miocardio Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Eur J Heart Fail Asunto de la revista: CARDIOLOGIA Año: 2021 Tipo del documento: Article